Published in AAPS J on March 03, 2010
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 2.27
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One (2011) 1.48
Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One (2013) 1.47
Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res (2011) 1.42
Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One (2012) 1.21
Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One (2012) 1.04
MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther (2014) 1.04
Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One (2011) 1.02
Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol (2014) 1.00
Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond) (2011) 0.91
Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. Am J Cancer Res (2015) 0.91
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem (2012) 0.90
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol (2014) 0.90
Hypoxic tumor environments exhibit disrupted collagen I fibers and low macromolecular transport. PLoS One (2013) 0.88
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Br J Cancer (2012) 0.87
Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways. PLoS One (2014) 0.87
The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther (2014) 0.86
The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma. Mol Cancer Res (2011) 0.84
Down-regulation of GEP100 causes increase in E-cadherin levels and inhibits pancreatic cancer cell invasion. PLoS One (2012) 0.83
Improved in vitro efficacy of gold nanoconstructs by increased loading of G-quadruplex aptamer. Nano Lett (2014) 0.83
Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3. Oncotarget (2015) 0.83
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis. Pancreas (2016) 0.80
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br J Pharmacol (2014) 0.80
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev (2015) 0.79
Generation of an in vitro 3D PDAC stroma rich spheroid model. Biomaterials (2016) 0.77
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer (2015) 0.77
Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. Cancers (Basel) (2015) 0.77
FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogenesis (2017) 0.75
Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World J Gastrointest Pathophysiol (2016) 0.75
Nanodelivery of Parthenolide Using Functionalized Nanographene Enhances its Anticancer Activity. RSC Adv (2015) 0.75
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget (2016) 0.75
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER. Ann Surg (1935) 26.74
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res (1999) 4.16
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol (2002) 4.15
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut (1998) 3.77
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature (2008) 3.05
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol (2005) 2.88
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas (2004) 2.85
The National Cancer Data Base report on pancreatic cancer. Cancer (1995) 2.77
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today (2003) 2.72
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 2.71
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch (2003) 2.53
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol (2009) 2.18
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer (1993) 2.14
Epidemiology of pancreatic cancer. Minerva Chir (2004) 2.14
Drug delivery and transport to solid tumors. Pharm Res (2003) 2.05
Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol (2009) 1.94
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol (2007) 1.86
Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas (2004) 1.67
Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int (2007) 1.67
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer (2008) 1.57
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol (1992) 1.54
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol (2008) 1.52
Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol (2006) 1.48
Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res (2006) 1.47
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology (2009) 1.43
Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest (2000) 1.40
Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen (2001) 1.37
Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology (1999) 1.37
A stem cell model of human tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst (1983) 1.35
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A (2000) 1.32
The integrin-extracellular matrix axis in pancreatic cancer. Pancreas (2007) 1.22
Pancreatic stellate cells--role in pancreas cancer. Langenbecks Arch Surg (2008) 1.21
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg (2008) 1.21
Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol (2008) 1.19
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Cancer. Breaching the cancer fortress. Science (2009) 1.15
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys (2008) 1.11
Cell migration: a novel aspect of pancreatic stellate cell biology. Gut (2003) 1.08
Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther (2008) 1.06
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer (2000) 1.05
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res (2006) 1.03
Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas (2009) 1.01
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys (2002) 1.01
Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today (2008) 0.99
Molecular targeted therapies for pancreatic cancer. Am J Surg (2008) 0.99
Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol (1997) 0.98
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg (2008) 0.98
Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol (2008) 0.97
Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst (2002) 0.96
Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int (2008) 0.95
Gene therapy developments for pancreatic cancer. Best Pract Res Clin Gastroenterol (2006) 0.92
Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg (2008) 0.92
The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett (1996) 0.90
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2008) 0.89
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
Drug delivery and transport to solid tumors. Pharm Res (2003) 2.05
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release (2013) 1.46
Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans. Clin Cancer Res (2007) 1.45
Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) (2010) 1.45
Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther (2007) 1.44
Intraperitoneal therapy for peritoneal cancer. Future Oncol (2010) 1.25
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
Protection against chemotherapy-induced alopecia. Pharm Res (2006) 1.22
Intravesical treatments of bladder cancer: review. Pharm Res (2008) 1.16
Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol (2005) 1.15
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev (2011) 1.11
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res (2007) 1.09
Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther (2008) 1.06
Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res (2005) 1.05
Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res (2003) 1.04
Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res (2004) 1.04
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res (2006) 1.03
Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res (2003) 0.94
Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond) (2011) 0.91
Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids. AAPS J (2013) 0.89
Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J (2011) 0.89
Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm (2011) 0.88
Intraprostatic chemotherapy: distribution and transport mechanisms. Clin Cancer Res (2005) 0.88
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res (2003) 0.87
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol (2012) 0.85
Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett (2002) 0.84
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2010) 0.83
Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol (2005) 0.82
Multiscale tumor spatiokinetic model for intraperitoneal therapy. AAPS J (2014) 0.82
Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res (2003) 0.82
Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance. J Transl Med (2008) 0.80
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res (2006) 0.80
Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res (2003) 0.80
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res (2004) 0.79
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res (2005) 0.79
Risk-adapted use of intravesical chemotherapy. BJU Int (2008) 0.79
Biodegradable intraprostatic doxorubicin implants. AAPS J (2007) 0.78
Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol (2011) 0.78
Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors. Curr Cancer Drug Targets (2014) 0.77
Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. J Pharmacol Exp Ther (2003) 0.77
Suramin as a chemosensitizer: oral pharmacokinetics in rats. Pharm Res (2004) 0.77
Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. AAPS J (2015) 0.77
Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma. J Am Anim Hosp Assoc (2013) 0.76
Combination intravesical hyperthermia and chemotherapy for bladder cancer. Oncology (Williston Park) (2010) 0.76
Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs. AAPS J (2010) 0.75
Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J (2014) 0.75
Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. J Vet Intern Med (2006) 0.75